Nektar Therapeutics (NKTR) Expected to Post Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.94) per share and revenue of $10.4250 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The company had revenue of $10.86 million during the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. On average, analysts expect Nektar Therapeutics to post $-9 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $70.68 on Thursday. The stock’s fifty day moving average is $65.52 and its two-hundred day moving average is $66.19. The firm has a market capitalization of $2.39 billion, a P/E ratio of -8.39 and a beta of 1.13. Nektar Therapeutics has a fifty-two week low of $21.02 and a fifty-two week high of $109.00.

Insider Activity

In other Nektar Therapeutics news, CEO Howard W. Robin sold 10,000 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the transaction, the chief executive officer owned 65,045 shares of the company’s stock, valued at $3,923,514.40. This trade represents a 13.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 5,681 shares of Nektar Therapeutics stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total transaction of $397,670.00. Following the sale, the insider owned 9,756 shares of the company’s stock, valued at approximately $682,920. This represents a 36.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 21,862 shares of company stock worth $1,379,205. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the period. Headlands Technologies LLC purchased a new stake in Nektar Therapeutics in the second quarter valued at approximately $65,000. Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics in the first quarter valued at approximately $68,000. Quarry LP acquired a new position in Nektar Therapeutics during the fourth quarter worth $85,000. Finally, Rhumbline Advisers lifted its stake in Nektar Therapeutics by 23.3% during the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 41,948 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NKTR shares. BTIG Research lifted their price target on Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, April 22nd. HC Wainwright raised their price target on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Finally, Citigroup increased their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.00.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.